Cargando…

Potential Benefits of Icosapent Ethyl on the Lipid Profile: Case Studies

The cardiovascular benefits of marine-derived omega-3 fatty acids are supported by epidemiologic and clinical studies. Both healthy patients and those with confirmed coronary heart disease are advised by the American Heart Association to consume omega-3 fatty acids either through dietary fatty fish...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hilleman, Daniel E., Malesker, Mark A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Libertas Academica 2014
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3914996/ https://www.ncbi.nlm.nih.gov/pubmed/24516343 http://dx.doi.org/10.4137/CMC.S13571

Ejemplares similares

Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE‐IT
por: Olshansky, Brian, et al.
Publicado: (2023)

Beyond cardiovascular medicine: potential future uses of icosapent ethyl
por: Bhatt, Deepak L, et al.
Publicado: (2020)

Icosapent ethyl for the treatment of severe hypertriglyceridemia
por: Fares, Hassan, et al.
Publicado: (2014)

Icosapent ethyl: scientific and legal controversies
por: Curfman, Gregory, et al.
Publicado: (2021)

Clinical results and mechanism of action of icosapent ethyl
por: Borghi, Claudio, et al.
Publicado: (2023)

Retrospective Case Series of Patients with Diabetes or Prediabetes Who Were Switched from Omega-3-Acid Ethyl Esters to Icosapent Ethyl
por: Hassan, Amir, et al.
Publicado: (2014)

Icosapent Ethyl (Vascepa®) for the Treatment of Acute, Severe Pancreatitis
por: Berger, Amnon A, et al.
Publicado: (2020)

Efficacy and safety of icosapent ethyl in hypertriglyceridaemia: a recap
por: Parhofer, Klaus G, et al.
Publicado: (2020)

Effect of Concomitant Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on the Pharmacokinetics of Atorvastatin
por: Braeckman, Rene A., et al.
Publicado: (2014)

Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT smoking
por: Miller, Michael, et al.
Publicado: (2022)

Management of patients with fibrosing interstitial lung diseases
por: Morrow, Lee E, et al.
Publicado: (2021)

Spotlight on Icosapent Ethyl for Cardiovascular Risk Reduction: Evidence to Date
por: Jia, Xiaoming, et al.
Publicado: (2020)

The Novelty of Icosapent Ethyl in the Management of Hypertriglyceridemia and Alleviating Cardiovascular Risk
por: Khan, Muhammad Shoaib, et al.
Publicado: (2021)

A Critical Review of Icosapent Ethyl in Cardiovascular Risk Reduction
por: Huston, Jessica, et al.
Publicado: (2023)

The potential population health impact of treating REDUCE-IT eligible US adults with Icosapent Ethyl
por: Derington, Catherine G., et al.
Publicado: (2022)

Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL
por: Majithia, Arjun, et al.
Publicado: (2021)

Three Cases of COVID-19 Pneumonia That Responded to Icosapent Ethyl Supportive Treatment
por: Suh, Winston, et al.
Publicado: (2020)

Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses
por: Peterson, Benjamin E., et al.
Publicado: (2020)

Benefit of icosapent ethyl on coronary physiology assessed by computed tomography angiography fractional flow reserve: EVAPORATE-FFR(CT)
por: Rabbat, Mark G, et al.
Publicado: (2023)

Icosapent Ethyl – A Successful Treatment for Symptomatic COVID-19 Infection
por: Berger, Amnon A, et al.
Publicado: (2020)

A randomized trial of icosapent ethyl in ambulatory patients with COVID-19
por: Kosmopoulos, Andrew, et al.
Publicado: (2021)

Effect of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Omeprazole Plasma Pharmacokinetics in Healthy Adults
por: Braeckman, Rene A., et al.
Publicado: (2014)

Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Pharmacokinetic Parameters of Rosiglitazone in Healthy Subjects
por: Braeckman, Rene A, et al.
Publicado: (2015)

Mechanisms of action, efficacy, and safety of icosapent ethyl: from bench to bedside
por: Bhatt, Deepak L
Publicado: (2020)

Cardiovascular Risk Reduction With Icosapent Ethyl: A Systematic Literature Review
por: Thakur, Mala, et al.
Publicado: (2020)

The reduction in cardiovascular risk in REDUCE-IT is due to eicosapentaenoic acid in icosapent ethyl
por: Steg, Ph Gabriel, et al.
Publicado: (2021)

Emphasis on Icosapent Ethyl for Cardiovascular Risk Reduction: A Systematic Review
por: Sutariya, Bansi, et al.
Publicado: (2022)

Rationale and design of REDUCE‐IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial
por: Bhatt, Deepak L., et al.
Publicado: (2017)

Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE‐IT
por: Selvaraj, Senthil, et al.
Publicado: (2022)

A systematic review of the cardiovascular risk of inhaled anticholinergics in patients with COPD
por: Hilleman, Daniel E, et al.
Publicado: (2009)

Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis
por: Brinton, Eliot A., et al.
Publicado: (2018)

Switching from EPA + DHA (Omega-3-acid Ethyl Esters) to High-Purity EPA (Icosapent Ethyl) in a Statin-Treated Patient with Persistent Dyslipidemia and High Cardiovascular Risk: A Case Study
por: Crandell, James R.
Publicado: (2016)

The Road to Approval: a Perspective on the Role of Icosapent Ethyl in Cardiovascular Risk Reduction
por: Wang, Xiaowen, et al.
Publicado: (2020)

Global eligibility and cost effectiveness of icosapent ethyl in primary and secondary cardiovascular prevention
por: Toth, Peter P., et al.
Publicado: (2023)

Icosapent Ethyl, a Pure Ethyl Ester of Eicosapentaenoic Acid: Effects on Circulating Markers of Inflammation from the MARINE and ANCHOR Studies
por: Bays, Harold E., et al.
Publicado: (2013)

Icosapent Ethyl Effects on Fatty Acid Profiles in Statin-Treated Patients With High Triglycerides: The Randomized, Placebo-controlled ANCHOR Study
por: Ballantyne, Christie M., et al.
Publicado: (2019)

Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment
por: Weintraub, William S., et al.
Publicado: (2022)

Cost-Effectiveness of Icosapent Ethyl (IPE) for the Reduction of the Risk of Ischemic Cardiovascular Events in Canada
por: Lachaine, Jean, et al.
Publicado: (2023)

The Emerging Role of Icosapent Ethyl in Patients with Cardiovascular Disease: Mechanistic Insights and Future Applications
por: Gupta, Ashish, et al.
Publicado: (2023)

The Effects of Statins, Ezetimibe, PCSK9-Inhibitors, Inclisiran, and Icosapent Ethyl on Platelet Function
por: Di Costanzo, Assunta, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_acr12ue6nn559g0gdh9t9i4dtr